Viewing Study NCT00072566


Ignite Creation Date: 2025-12-24 @ 4:35 PM
Ignite Modification Date: 2026-01-27 @ 4:42 PM
Study NCT ID: NCT00072566
Status: COMPLETED
Last Update Posted: 2015-05-12
First Post: 2003-11-04
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Sponsor: National Cancer Institute (NCI)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Peritoneal Carcinoma View
None Recurrent Ovarian Carcinoma View
None Stage IV Ovarian Cancer View
Keywords: